Management Team
Dr. Robert F. Ryan, President and CEO:
Dr. Robert F. Ryan was named President and Chief Executive Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.
Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.
Dr. Gerald W. Crabtree, COO:
Dr. Crabtree was recently named the Chief Operating Officer. Even in such a short period as a few weeks, he has provided a significant benefit and impact for Nuvilex, clearly matching not only the commitment to repositioning Nuvilex into the biotechnology area, but also adds to the strength of our existing products and pipeline. I have worked with Dr. Crabtree and look forward to working with him to move Nuvilex forward. He has extensive experience in the areas of natural and synthetic drug and device research and development, having worked in both academia and small and large company environments. His business and financial acumen together with his research and development background combine to make him an invaluable addition to Nuvilex.
Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles, and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.
Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. He has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation. Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions, and contracts and business plans.
Patricia Gruden, Chairman of the Board of Directors and CFO:
Ms. Patricia Gruden has made a substantial impact in many companies over the years. It was in 1995 that she became cofounder of the company that has since become Nuvilex. The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance, and everything else concerning the distribution of produce worldwide. In addition, the company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. The company and its footprint expanded, eventually giving rise to the start of the publicly traded Nuvilex, Inc. Company's roots in 2001.
Ms. Gruden has carried out almost every job in the company over the years including developer, shipper, President, CEO, Chairman of the Board, CFO and many others. As a result, she has been intricately aware of all aspects of the company and its products throughout its history. After a short semi-retirement in 2009-10, she returned with renewed vigor and has since put in extensive effort and funding into returning the business to its former capabilities. Although her history and training has been focused in management and sales, she clearly has made substantial advances for Nuvilex.
Her training has not only included the real world experiences of running more than one company, but was well founded in her attainment of her B.S. degree in Business at the University of Oklahoma. From there, things have never been the same, propelling her to embrace every business opportunity with excitement, clarity and focus. Through the years, Patricia has had a long history of owning her own businesses, and doing so successfully, with her strengths in working with people, marketing and management. As part of her contribution and success at Nuvilex, she is President of some of the subsidiaries including Cinnergen, Inc. where she ensures organization, marketing, cash flow, and good management. Currently, Ms. Patricia Gruden is the Chairman of the Board of Directors and CFO for Nuvilex, guaranteeing a good dose of knowledge and success for the company through efficient and thoughtful oversight of the entire company and good fiscal management of our assets.
Dr. Robert F. Ryan was named President and Chief Executive Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.
Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.
Dr. Gerald W. Crabtree, COO:
Dr. Crabtree was recently named the Chief Operating Officer. Even in such a short period as a few weeks, he has provided a significant benefit and impact for Nuvilex, clearly matching not only the commitment to repositioning Nuvilex into the biotechnology area, but also adds to the strength of our existing products and pipeline. I have worked with Dr. Crabtree and look forward to working with him to move Nuvilex forward. He has extensive experience in the areas of natural and synthetic drug and device research and development, having worked in both academia and small and large company environments. His business and financial acumen together with his research and development background combine to make him an invaluable addition to Nuvilex.
Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles, and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.
Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. He has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation. Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions, and contracts and business plans.
Patricia Gruden, Chairman of the Board of Directors and CFO:
Ms. Patricia Gruden has made a substantial impact in many companies over the years. It was in 1995 that she became cofounder of the company that has since become Nuvilex. The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance, and everything else concerning the distribution of produce worldwide. In addition, the company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. The company and its footprint expanded, eventually giving rise to the start of the publicly traded Nuvilex, Inc. Company's roots in 2001.
Ms. Gruden has carried out almost every job in the company over the years including developer, shipper, President, CEO, Chairman of the Board, CFO and many others. As a result, she has been intricately aware of all aspects of the company and its products throughout its history. After a short semi-retirement in 2009-10, she returned with renewed vigor and has since put in extensive effort and funding into returning the business to its former capabilities. Although her history and training has been focused in management and sales, she clearly has made substantial advances for Nuvilex.
Her training has not only included the real world experiences of running more than one company, but was well founded in her attainment of her B.S. degree in Business at the University of Oklahoma. From there, things have never been the same, propelling her to embrace every business opportunity with excitement, clarity and focus. Through the years, Patricia has had a long history of owning her own businesses, and doing so successfully, with her strengths in working with people, marketing and management. As part of her contribution and success at Nuvilex, she is President of some of the subsidiaries including Cinnergen, Inc. where she ensures organization, marketing, cash flow, and good management. Currently, Ms. Patricia Gruden is the Chairman of the Board of Directors and CFO for Nuvilex, guaranteeing a good dose of knowledge and success for the company through efficient and thoughtful oversight of the entire company and good fiscal management of our assets.
